THE ECONOMIC RATIONALE FOR THE USE OF OUTPATIENT PLEURODESIS IN THE TREATMENT OF MALIGNANT PLEURAL EFFUSIONS

Introduction. Exudative tumor pleurisy affects up to 100 000 people a year in Russia, up to 400 000 people a year in Europe. Inpatient treatment of such patients is associated with certain costs, and there are also queues for treatment in oncology hospitals. An outpatient pleurodesis can reduce these problems.

The objective was to compare pharmacoeconomic parameters for inpatient pleurodesis and outpatient pleurodesis to determine the most cost-effective treatment option.

Methods and materials. 179 patients in the clinic of the Federal State Budgetary Institution Scientific Research Center for Oncology named after N. N. Petrov of the Russian Ministry of Health underwent pleurodesis using various methods (talc, bleocin, combined). The effectiveness of the methods and the direct medical costs of treatment were evaluated. The effectiveness of a stationary thoracoscopic pleurodesis was evaluated according to foreign literature, and the direct medical costs of treatment were calculated. Based on the obtained results, the pharmacoeconomic indicators of CER and ICER were calculated.

Results. Direct medical costs for stationary thoracoscopic pleurodesis amounted to 35056.4 rubles with an efficiency of 89 %. Direct medical costs for outpatient pleurodesis were: for talc pleurodesis – 8051.7 rubles, for bleocin and combined pleurodesis – 11799.2 rubles. CER amounted to: for a thoracoscopic pleurodesis in the hospital – 393.9, for talc pleurodesis – 115.35, for bleocin pleurodesis – 188.7, for combined pleurodesis – 155.8. ICER in relation to stationary pleurodesis was 1406.4 for talc pleurodesis, 877.6 for bleocin pleurodesis, 1748.6 for combined pleurodesis.

Conclusion. CER was almost 3 times lower with outpatient pleurodesis, which makes it the most cost-effective option for the treatment of tumor exudative pleurisy. ICER was maximal in combined pleurodesis, which makes it preferred among outpatient pleurodesis options. Based on the obtained data, it can be argued that the use of ambulatory pleurodesis as an initial stage of care for patients with tumor exudative pleurisy is economically justified.

1. Antony V., Lodderkemper R., Astoul P., Boutin K., Goldtraw P., Hott J., Panadero F. R., Sahn S. A. Management of Malignant Pleural Effusions. Am J Respir Crit Care Med. 2000;162:1987–2001.

2. Nikbakhsh N., Pourhasan Amiri A., Hoseinzadeh D. Bleomycinin thetreatment of 50 cases with malignant pleural effusion. Caspian J Intern Med. 2011;2(3):274–278.

3. Roberts M. E., Neville E., Berrisford R. G., Antunes G., Ali N. J., BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(2):32–40.

4. Puri V., Pyrdeck T. L., Crabtree T. D., Kreisel D., Krupnick A. S., Colditz G. A., Patterson G. A., Meyers B. F. Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg. 2012;94(2):374–380.

5. Olden A. M., Holloway R. Treatment of Malignant Pleural Effusion: PleuRx Catheter or Talc Pleurodesis? A Cost-Effectiveness Analysis. Journal Of Palliative Medicine. 2010;13(1):59–65.

6. Olfert Jordan A. P., Penz Erika D., Manns Braden J., Mishra E. K., Davies H. E., Miller R. F., Luengo-Fernandez R., Gao S., Rahman N. M. Cost-effectiveness of indwelling pleural catheter compared with talc in malignant pleural effusion. Respirology. 2017;22:764–770.

7. Tarifnoe soglashenie na oplatu medicinskoj pomoshchi, okazyvaemoj po territorial’noj programme obyazatel’nogo medicinskogo strahovaniya goroda Sankt-Peterburga na 2019 god s prilozheniyami. (In Russ.). Available at: https://spboms.ru/sites/default/files/terrpro/gts_na_2019_0.zip (accessed: 10.10.2019).

8. Otraslevoj standart «Kliniko-ekonomicheskie issledovaniya. Obshchie polozheniya» Prikaz Minzdrava RF ot 27.05.2002 № 163 vmeste s ost 91500.14.0001-2002. (In Russ.). Available at: http://www.healtheconomics.ru/index.php?option=com_content&view=article&id=300:-qq&catid=55:2009-05-29-19-56-44&Itemid=104 (accessed: 10.10.2019).

9. Musina N. Z., Fedyaeva V. K. Metody rascheta qaly kak integral’nogo pokazatelya effektivnosti v processe kompleksnoj ocenki lekarstvennyh preparatov. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2017;10(1):66–71. (In Russ.).

10. Yagudina R. I., Kulikov A. Yu., Metelkin I. A. Metodologiya analiza «zatraty-effektivnost’» pri provedenii farmakoekonomicheskih issledovanij. Farmakoekonomika. 2012; 5(4):3–8. (In Russ.).

11. Yagudina R. I., Serpik V. G., Kulikov A. Yu. Farmakoekonomika dlya organizatorov zdravoohraneniya. algoritm prinyatiya reshenij na osnove farmakoekonomicheskoj ocenki. Farmakoekonomika: Teoriya i praktika. 2014;2(1):5–12. (In Russ.).

12. Nafees B., Stafford M., Gavriel S., Bhalla S., Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.

13. Prikaz Ministerstva zdravoohraneniya Rossijskoj Federacii ot 28 dekabrya 2012 g. № 1592n «Ob utverzhdenii standarta specializirovannoj medicinskoj pomoshchi pri plevrite». (In Russ.).